Steward Partners Investment Advisory LLC Takes Position in Liquidia Co. (NASDAQ:LQDA)

Steward Partners Investment Advisory LLC purchased a new stake in shares of Liquidia Co. (NASDAQ:LQDA) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,000 shares of the company’s stock, valued at approximately $59,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Walleye Trading LLC boosted its position in shares of Liquidia by 54.7% during the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after acquiring an additional 4,670 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Liquidia by 43.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company’s stock valued at $187,000 after acquiring an additional 5,669 shares during the last quarter. DMC Group LLC lifted its position in Liquidia by 17.4% in the fourth quarter. DMC Group LLC now owns 16,302 shares of the company’s stock valued at $192,000 after buying an additional 2,419 shares during the last quarter. Intech Investment Management LLC acquired a new position in Liquidia in the third quarter valued at about $195,000. Finally, Catalina Capital Group LLC lifted its position in Liquidia by 6.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock valued at $215,000 after buying an additional 1,125 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Stock Performance

Shares of LQDA opened at $14.74 on Wednesday. The stock has a market capitalization of $1.25 billion, a PE ratio of -9.04 and a beta of 0.07. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $16.99. The company’s 50-day simple moving average is $14.62 and its 200-day simple moving average is $12.10.

Insider Transactions at Liquidia

In related news, CFO Michael Kaseta sold 23,370 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $73,613.22. Following the sale, the insider now owns 270,388 shares in the company, valued at $3,185,170.64. The trade was a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,245 shares of company stock valued at $843,326. 30.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on LQDA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of Liquidia in a research report on Thursday, January 9th. Wells Fargo & Company started coverage on shares of Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $25.38.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).